Navigation Links
Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
Date:5/22/2013

SAN DIEGO, May 22, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 31 through June 4, 2013, at McCormick Place in Chicago.

Information about the abstracts, including presentation time and location, is listed below. Abstracts can be viewed online at http://abstracts2.asco.org/. Abstract No:
7023Title:Efficacy and Safety of Quizartinib (AC220) in Patients Aged > / = 70 Years with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (AML)Presenter:Alexander Perl, M.D. (University of Pennsylvania)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7012Title:High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation (HSCT) with Quizartinib (AC220) in Patients with FLT3 ITD Positive or Negative Relapsed/Refractory AML After Second Line Chemotherapy or Previous Bone Marrow TransplantPresenter:Jorge Cortes, M.D. (MD Anderson Cancer Center, University of Texas)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7021Title:Quizartinib (AC220) Produces High Response Rates and Long Term Survival in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid LeukemiaPresenter:Giovanni Martinelli, M.D., Ph.D. (University of Bologna School of Medicine)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406 

About QuizartinibQuizartinib (AC220) is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently under evaluation in a Phase 2b clinical trial as monotherapy treatment for adult patients with relapsed or refractory AML, and in two Phase 1 studies in a combination treatment regimen with chemotherapy, and as a maintenance therapy following transplant, respectively.

About Ambit BiosciencesAmbit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future therapeutic and commercial potential of Ambit's lead drug candidate and pipeline, business plans, technologies and intellectual property. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts: 
Ian Stone or David Schull (Media) 
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com 
david.schull@russopartnersllc.com

 

 


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
2. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
3. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
6. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
10. Neurocrine Biosciences Reports First Quarter 2012 Results
11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LA JOLLA, Calif. , Feb. 23, 2017 /PRNewswire/ ... biopharmaceutical company leading the discovery and development of innovative ... quarter and full year 2016 financial results on Thursday, ... Regulus will host a conference call and webcast on ... discuss fourth quarter and full year 2016 financial results ...
(Date:2/23/2017)... -- According to a new market research ... Analog), MRI (Closed, Open), Ultrasound, CT, Nuclear Imaging (SPECT, ... (Hospitals, Imaging Centers) - Global Forecast to 2021", published ... the forecast period of 2016 to 2021. The market ... at a CAGR of 6.6% from 2016 to 2021. ...
(Date:2/23/2017)... Feb 23, 2017 ... Research and Markets has announced the addition of ... to 2025" report to their offering. The Global ... 1.8% over the next decade to reach approximately $12.8 billion by 2025. ... forecasts for all the given segments on global as well as regional ...
Breaking Medicine Technology:
(Date:2/24/2017)... Pittsburgh, PA (PRWEB) , ... February 24, 2017 , ... ... by researchers at the University of Pittsburgh points to eight genes that may explain ... the other, according to the results of a study published today in the journal ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ... is so critically important that we all are aware of our options and ... is proud to announce the launch of its newest edition of "Vision and ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for ... engaged in or interested in palliative care education and research. The Symposium, “Innovate. ... North County San Diego on Sept. 28 and 29, 2017, on the campus of ...
Breaking Medicine News(10 mins):